Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Growth Hormone Releasing Peptide-6
Also known as: Growth Hormone Releasing Hexapeptide, SKF-110679, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Confidence
Updated 2026-03-18
GHRP-6 is a synthetic hexapeptide that potently stimulates growth hormone release via the ghrelin receptor. It was one of the earliest GHRPs discovered and is notable for its strong appetite-stimulating effects (mediated by ghrelin pathway activation). It has been widely used in research settings for GH axis assessment and body composition studies.
Class
GH Secretagogue (GHRP)
Routes
Subcutaneous, Intravenous
Half-Life
~15–60 minutes
GHRP-6 binds to the GHS-R1a (ghrelin receptor) on pituitary somatotrophs and hypothalamic neurons, stimulating GH release through both direct pituitary action and hypothalamic GHRH release. It strongly activates ghrelin signaling, producing significant hunger. Also transiently increases cortisol, prolactin, and ACTH at higher doses.
Half-Life
~15–60 minutes
Bioavailability
Subcutaneous: ~60–70% (estimated)
No approved indications. Research: GH deficiency assessment, appetite stimulation in cachexia, body composition research, GH axis physiology studies.
Well-characterized in human pharmacology studies. Reliably stimulates GH release in a dose-dependent manner. Used as a diagnostic tool for GH deficiency in some research protocols. Limited therapeutic trial data — most studies are acute pharmacology or short-term. Appetite stimulation is pronounced and limits tolerability for some applications.
Human Studies
25
Animal Studies
60
Common: intense hunger/appetite stimulation, water retention, cortisol elevation, transient prolactin increase. Gastric discomfort. May worsen glucose tolerance. Less selective than ipamorelin — more off-target hormonal effects.
Investigational. Widely available as a research peptide. WADA-prohibited in sport. No FDA regulatory pathway currently active.
Drug Interactions: Caution with corticosteroids, diabetes medications, and appetite suppressants. Monitoring: GH, IGF-1, cortisol, prolactin, fasting glucose. Research Gaps: No large-scale therapeutic trials. Appetite stimulation may limit clinical utility in most populations.
Subcutaneous (research context)
Common Range
100–300 mcg/dose
Timing
Fasted (at least 30 min before food) or pre-bedtime
Frequency
1–3 times daily
Cycling
4–12 weeks, cycling recommended
Reconstitution
Reconstitute lyophilized powder with bacteriostatic water
Storage
Refrigerated after reconstitution
Important Note
NOT FDA-approved. Strong appetite increase expected. Best combined with GHRH analog (CJC-1295) for synergistic GH release.
Connect with a verified provider offering GHRP-6 therapy near you.
GH Secretagogue (GHRP)
GHRP-2 is a synthetic hexapeptide GH secretagogue considered the most potent GHRP in terms of GH release per dose. It is approved in Japan as a diagnostic agent for GH deficiency (under the name Pralmorelin). It provides a strong GH stimulus with moderate appetite effects — positioned between the hunger-inducing GHRP-6 and the clean-profile ipamorelin.
GH Secretagogue
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to stimulate GH release from the pituitary. It is considered one of the most selective GH secretagogues, with minimal effect on cortisol, prolactin, and other hormones — making it a preferred choice in combination protocols with CJC-1295.
GH Secretagogue (GHRP)
Hexarelin is a synthetic hexapeptide growth hormone secretagogue and one of the most potent GHRPs studied. It stimulates GH release via the ghrelin receptor and has unique cardioprotective properties independent of its GH-releasing activity. Despite promising research, it was never brought to market due to tachyphylaxis (reduced response with repeated dosing).
GH Secretagogue
CJC-1295 is a synthetic analog of GHRH(1-29) with modifications to extend its half-life. Available in two forms: with Drug Affinity Complex (DAC) for prolonged action, and without DAC (also called Modified GRF 1-29) for shorter, more pulsatile action. Frequently combined with ipamorelin for synergistic GH release.
GHRH Analog
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. Originally FDA-approved for diagnostic use in assessing growth hormone secretion, it has become a cornerstone of legitimate peptide therapy for growth hormone optimization due to its established safety profile and compounding eligibility.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.